25 results for “synucleinopathy”. Showing 25 of 39,449.
Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
synucleinopathies. Clinically, synucleinopathies are heterogeneous, reflecting the somewhat selective neuronal
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
synucleinopathies. Two murine models of synucleinopathy (a Gaucher-related synucleinopathy
Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies.
synucleinopathies. Actin pathology occurred in iPSC synucleinopathy models and RhoA
Structure-function relationship of alpha-synuclein fibrillar polymorphs derived from distinct synucleinopathies.
synucleinopathies, for which the pathobiology is not well understood. The different
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
synucleinopathies, including Parkinson's disease (PD). Although the precise triggers
Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies.
synucleinopathies. Currently, diagnosis of synucleinopathies is based on the clinical
Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies.
synucleinopathy such as dementia with Lewy bodies and Parkinson's disease
Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
synucleinopathies. Importantly, the identification of missense mutations in alpha-synuclein
GBA-associated parkinsonism and dementia: beyond α-synucleinopathies?
synucleinopathies in the parkinsonism-dementia spectrum is still unclear. The aim of the study
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson's disease.
synucleinopathies such as Parkinson's disease (PD), dementia with Lewy
Galantamine suppresses α-synuclein aggregation by inducing autophagy via the activation of α
Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies
In-vivo evidence of synucleinopathy in parkinsonism due to VCP mutation.
synucleinopathy. We report a case of VCP-related parkinsonism providing
TNF-α-NF-κB activation through pathological α-Synuclein disrupts the BBB and exacerbates axonopathy.
synucleinopathy, on BBB integrity and function and identify therapeutic targets
STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy.
synucleinopathies. Herein, we used primary cell cultures and the intrastriatal
Peripheral α-synuclein isoforms are potential biomarkers for diagnosis and prognosis of isolated REM sleep behavior disorder.
synucleinopathies Parkinson's disease (PD) and dementia with Lewy bodies
REM sleep behaviour disorder.
synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple
Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.
synucleinopathy. We previously performed a genetic screen for modifiers of α-Syn levels
Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
synucleinopathy may identify therapeutic targets. Here we characterized the neuroinflammatory
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.
synucleinopathies that include PD, dementia with Lewy bodies (DLB) and multiple
Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials.
synucleinopathy. METHODS: In a 10-year prospective cohort, we tested
Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.
synucleinopathy, and associated events, including nigral dopaminergic cell death, oxidative
α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders.
Synucleinopathies such as Parkinson's disease (PD) and multiple system
Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts.
synucleinopathies. Using biophysical, biochemical and cell-culture-based assays, assessment
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
synucleinopathies aiming to decrease the SNCA burden.Abbreviations: aa: amino acid
Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.
Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized